Sharp Edge Labs, a former NSIV member, and ORIG3N have recently announced an alliance that will help create patient-specific disease treatments. “We are now involving patients earlier in the drug discovery process – this is a special moment in medicine.” Said Scott Sneddon, CEO of Sharp Edge Labs. “By combining our technologies, we are tailoring treatments for specific patient populations from the very beginning, with the aim of delivering disease modifying agents for diseases of high unmet need.”
Leave a Comment